RxDoctor Payments Data

Molly Brockman, MD

Internal Medicine · Shepherdsville, KYNPI 1932594736

Payments from drug & device makers

$99in general payments, 2019–2025

Across 7 payments — averaging $14.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$28
  • Amgen$19
  • Mylan Specialty L.p.$15
  • AstraZeneca$14
  • GSK$12
  • Merck$11

What the payments were for

  • Food & beverage$99100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk2$28
Amgen1$19
Mylan Specialty L.p.1$15
AstraZeneca1$14
GSK1$12
Merck1$11

How this compares

$99 in reported general payments places this provider in the 30th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$127,230
Medicare patients
324
Services billed
2,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide138$138,425
EliquisApixaban111$95,987
JardianceEmpagliflozin52$79,672
TrulicityDulaglutide35$51,807
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$34,601
MounjaroTirzepatide29$31,926
LinzessLinaclotide20$27,746
FarxigaDapagliflozin Propanediol34$25,240
JanuviaSitagliptin Phosphate12$18,893
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$17,744
XareltoRivaroxaban31$17,000
Tresiba Flextouch U-100Insulin Degludec11$12,447
Repatha SureclickEvolocumab14$9,637
Breo ElliptaFluticasone/Vilanterol14$9,337
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$8,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$28$138,425138 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$12$49,01469 claims
AstraZenecaFarxiga$14$25,24034 claims
MerckJanuvia$11$18,89312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Shepherdsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →